Clinical Trial

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Study acronym: SAV
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 15, 2023 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-12.
Status change: Not Yet Recruiting → Recruiting 2023-03-13
Trial Details
NCT Number NCT05736965
Lead Sponsor Shanghai Tong Ren Hospital
Conditions AML, Adult
Enrollment 58 participants
Start Date 2023-02-20
Primary Completion 2025-03-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2023-03-15